Lung cancer remains the most lethal cancer worldwide, and traditional biopsy approaches still leave critical gaps. In this episode, interventional pulmonologist Dr. Steven Kovacs shares how real-time metabolic imaging inside the bronchoscopy suite is transforming how clinicians assess biopsy adequacy.

Episode Breakdown

00:00 – Opening remarks: the challenge of lung cancer diagnosis

01:17 – Introducing Dr. Steven Kovacs

02:11 – Journey through bronchoscopy: from navigation to robotics

05:11 – The problem with current biopsy yields and ROSE

07:29 – Why imaging tool-in-lesion is not enough

09:59 – Metabolic activity as a new “PET scan for cells”

12:16 – How dynamic cell imaging works in real time

14:45 – Preserving tissue for pathology and sequencing

17:15 – Differentiating inflammation, necrosis, and malignancy in the same lesion

19:37 – Case studies: when pathology said “negative,” but malignancy was present

22:01 – Adequacy as a clinical responsibility, not just pathology’s burden

24:07 – The future of bronchoscopy workflows and precision medicine

27:32 – Audience Q&A: diagnostic adequacy and workflow efficiency

30:52 – Audience Q&A: reducing procedure time and anesthesia costs

34:41 – Audience Q&A: handling tissue and specimen prep

38:18 – Audience Q&A: impact on indeterminate biopsies

43:12 – Audience Q&A: adequacy for NGS and downstream testing

47:20 – Hospital administration and value analysis: time savings and cost impact

50:05 – Surgical use cases and margin evaluation

52:25 – Adoption and workflow integration: overcoming learning curves

53:32 – Closing thanks and replay reminder

Are you a medtech CEO in need of some marketing help attracting investors, growing sales pipeline, and more? Go to ⁠⁠⁠GrowMyMedtech.com⁠⁠⁠ to book time for a free analysis.

Subscribe to our Youtube Channel

⁠⁠⁠https://www.youtube.com/channel/UCGpL_rGt1LQJwinMq_K7gfg⁠⁠⁠

Subscribe to our LinkedIn Newsletter

⁠⁠⁠https://www.stateofmedtechpodcast.com/⁠⁠⁠

Follow The State of MedTech on

LinkedIn ⁠⁠⁠https://www.linkedin.com/company/thestateofmedtech⁠⁠⁠

Instagram ⁠⁠⁠https://www.instagram.com/stateofmedtech/⁠⁠⁠

TikTok ⁠⁠⁠https://www.tiktok.com/@stateofmedtech⁠⁠⁠

X ⁠⁠⁠https://twitter.com/StateofMedTech⁠⁠⁠

Facebook ⁠⁠⁠https://www.facebook.com/stateofmedtech/⁠⁠⁠

Follow Omar M. Khateeb on

LinkedIn ⁠⁠⁠https://www.linkedin.com/in/okhateeb/⁠⁠⁠

Instagram ⁠⁠⁠https://www.instagram.com/omar.m.khateeb/⁠⁠⁠

TikTok ⁠⁠⁠https://www.tiktok.com/@omarkhateebofficial⁠⁠⁠

X ⁠⁠⁠https://twitter.com/OmarMKhateeb⁠⁠⁠

Facebook ⁠⁠⁠https://www.facebook.com/OmarMKhateeb/⁠⁠

#Medtech #LungCancer #Diagnostics #Pulmonology #HealthcareInnovation

Tetiana Aleksandrova, CEO and founder of Subsense, explains how her team is building a nanoparticle-based Brain Computer Interface designed to treat symptoms of neurological disorders while unlocking new possibilities for human cognition.

Episode Breakdown:00:00 – Opening and long-term vision for merging humans with technology01:10 – Guest introduction: Tetiana Aleksandrova, CEO and founder of Subsense
02:01 – Personal journey: from chemistry to economics to serial BCI entrepreneur03:38 – Lessons learned from her first EEG-based BCI company05:25 – Why Subsense pivoted to nanoparticle-based BCIs06:52 – The problem with current treatments for neurodegenerative diseases07:40 – Non-surgical alternatives to deep brain stimulation09:35 – Nanoparticles as antennas for brain signals12:20 – Duration, delivery methods, and safety of nanoparticles13:04 – First clinical targets: Parkinson’s and epilepsy14:50 – Why non-surgical BCIs excite clinicians and investors16:05 – Expanding into broader neurological disorders and cognitive enhancement17:02 – Device design and hardware considerations18:19 – Why separate nanoparticles are needed for reading and stimulation20:01 – Collaborations with UC Santa Cruz and ETH Zurich21:08 – Regulatory challenges and breakthrough designation pathway22:21 – How stimulation nanoparticles work in the brain25:01 – Potential beyond medicine: memory, focus, and human performance28:14 – Public demand for cognitive optimization since COVID
30:33 – The AI revolution and parallels with the BCI revolution
33:01 – Why BCIs could be the next major technological shift
34:20 – $17M funding round led by Golden Falcon Capital and Palo Alto lab launch
36:45 – Future milestones and how to connect with Subsense

Are you a medtech CEO in need of some marketing help attracting investors, growing sales pipeline, and more? Go to ⁠⁠GrowMyMedtech.com⁠⁠ to book time for a free analysis.

Subscribe to our Youtube Channel

⁠⁠https://www.youtube.com/channel/UCGpL_rGt1LQJwinMq_K7gfg⁠⁠

Subscribe to our LinkedIn Newsletter

⁠⁠https://www.stateofmedtechpodcast.com/⁠⁠

Follow The State of MedTech on

LinkedIn ⁠⁠https://www.linkedin.com/company/thestateofmedtech⁠⁠

Instagram ⁠⁠https://www.instagram.com/stateofmedtech/⁠⁠

TikTok ⁠⁠https://www.tiktok.com/@stateofmedtech⁠⁠

X ⁠⁠https://twitter.com/StateofMedTech⁠⁠

Facebook ⁠⁠https://www.facebook.com/stateofmedtech/⁠⁠

Follow Omar M. Khateeb on

LinkedIn ⁠⁠https://www.linkedin.com/in/okhateeb/⁠⁠

Instagram ⁠⁠https://www.instagram.com/omar.m.khateeb/⁠⁠

TikTok ⁠⁠https://www.tiktok.com/@omarkhateebofficial⁠⁠

X ⁠⁠https://twitter.com/OmarMKhateeb⁠⁠

Facebook ⁠⁠https://www.facebook.com/OmarMKhateeb/⁠

#BCI #Neurotech #Medtech #HealthcareInnovation #BrainComputerInterface #DigitalHealth #Neuroscience

Brain Computer Interfaces are gaining traction across healthcare and beyond. Meron Gibertz and Dr. Darin Dougherty discuss how BCIs capture and process signals, their growing medical use cases, and the hurdles in regulation, ethics, and safety.

Episode breakdown:

00:00 – Opening and introduction00:48 – Introducing Meron Gibertz and Dr. Darin Dougherty02:11 – What is a brain-computer interface (BCI)?04:36 – Evolution of BCI technology07:02 – How BCIs work: signals and processing10:28 – Clinical applications in healthcare13:55 – Non-medical applications and future potential17:40 – Challenges in ethics, privacy, and safety21:16 – Industry landscape and current players25:04 – Recent breakthroughs and research highlights29:12 – Regulatory pathways and adoption barriers32:40 – The road ahead: opportunities and risks32:40 – Closing thoughts and final takeaways

#Medtech #BrainComputerInterface #BCI #HealthcareInnovation #Neurotech #DigitalHealth #MedicalDevices

Are you a medtech CEO in need of some marketing help attracting investors, growing sales pipeline, and more? Go to ⁠⁠GrowMyMedtech.com⁠⁠ to book time for a free analysis.

Subscribe to our Youtube Channel

⁠⁠https://www.youtube.com/channel/UCGpL_rGt1LQJwinMq_K7gfg⁠⁠

Subscribe to our LinkedIn Newsletter

⁠⁠https://www.stateofmedtechpodcast.com/⁠⁠

Follow The State of MedTech on

LinkedIn ⁠⁠https://www.linkedin.com/company/thestateofmedtech⁠⁠

Instagram ⁠⁠https://www.instagram.com/stateofmedtech/⁠⁠

TikTok ⁠⁠https://www.tiktok.com/@stateofmedtech⁠⁠

X ⁠⁠https://twitter.com/StateofMedTech⁠⁠

Facebook ⁠⁠https://www.facebook.com/stateofmedtech/⁠⁠

Follow Omar M. Khateeb on

LinkedIn ⁠⁠https://www.linkedin.com/in/okhateeb/⁠⁠

Instagram ⁠⁠https://www.instagram.com/omar.m.khateeb/⁠⁠

TikTok ⁠⁠https://www.tiktok.com/@omarkhateebofficial⁠⁠

X ⁠⁠https://twitter.com/OmarMKhateeb⁠⁠

Facebook ⁠⁠https://www.facebook.com/OmarMKhateeb/⁠

#Medtech #HealthcareBusiness #EarningsSeason #MedicalDevices #Robotics

Strong earnings, mega-deals, and a robotics shake-up highlight medtech’s Q2. Nicholas Talamantes joins to cover the numbers, the moves, and the strategies setting the tone for the second half of the year.

Episode Breakdown:

00:00 – Opening and show introduction

01:02 – Meet guest Nicholas Talamantes and episode agenda

02:02 – Q2 earnings overview and market growth

05:15 – Spin-outs, mega-deals, and the venture ecosystem

08:39 – Key takeaways from a strong Q2

09:01 – Trade policy, tariffs, and AI regulation

14:25 – Trending stories: cardiology leads funding

16:57 – Acquisitions and diagnostics momentum

19:12 – Chronic disease management and IVD growth

22:01 – Strategic divestitures across medtech

24:44 – Robotics market snapshot and trends

28:52 – Olympus and Revival: robotic endoscopy push

31:21 – Fractal Health and Aqua Medical innovations

33:59 – Think Surgical and platform competition

35:28 – Biggest deals and raises in Q2

37:32 – Zimmer Biomet to acquire Monogram

41:56 – Favorite deals: Cardamon PFA and Nēros Medical

44:36 – Wrap-up and medtech resilience

45:14 – Compass platform and Europe plans

46:50 – Closing thanks and subscribe

Are you a medtech CEO in need of some marketing help attracting investors, growing sales pipeline, and more? Go to ⁠GrowMyMedtech.com⁠ to book time for a free analysis.

Subscribe to our Youtube Channel

⁠https://www.youtube.com/channel/UCGpL_rGt1LQJwinMq_K7gfg⁠

Subscribe to our LinkedIn Newsletter

⁠https://www.stateofmedtechpodcast.com/⁠

Follow The State of MedTech on

LinkedIn ⁠https://www.linkedin.com/company/thestateofmedtech⁠

Instagram ⁠https://www.instagram.com/stateofmedtech/⁠

TikTok ⁠https://www.tiktok.com/@stateofmedtech⁠

X ⁠https://twitter.com/StateofMedTech⁠

Facebook ⁠https://www.facebook.com/stateofmedtech/⁠

Follow Omar M. Khateeb on

LinkedIn ⁠https://www.linkedin.com/in/okhateeb/⁠

Instagram ⁠https://www.instagram.com/omar.m.khateeb/⁠

TikTok ⁠https://www.tiktok.com/@omarkhateebofficial⁠

X ⁠https://twitter.com/OmarMKhateeb⁠

Facebook ⁠https://www.facebook.com/OmarMKhateeb/

#Medtech #HealthcareBusiness #EarningsSeason #MedicalDevices #Robotics

Most prosthetic users still manage comfort with socks, a system that’s decades old. Vessl Prosthetics, led by CEO Sydney Robinson, is tackling the biggest pain point in lower-limb prosthetics: poor fit.
From automatic adjustment technology to a clear reimbursement path, Sydney shares how Vessl is positioned to dominate a half-billion-dollar market.

Episode breakdown:

0:00 – Why Sydney Chose Prosthetics

0:38 – Back From LSI & Discovering Sydney’s Pitch

1:15 – Meet Sydney Robinson & Vessl Prosthetics

2:12 – Sydney’s Background & Path to Prosthetics

3:48 – The Big Problem in Prosthetic Fit

5:11 – The Sock Analogy & Comfort Issues

6:18 – Why It’s Called Vessl

7:37 – Product Walkthrough & How It Works

11:44 – Business Model & Market Opportunity

12:39 – Why Vessl Can Dominate the Market

13:52 – Pricing, Reimbursement & Competitive Edge

17:22 – Overcoming “Not Sexy” Industry Perception

19:18 – US Amputee Stats & Global Growth

21:16 – Regulatory Pathway & Launch Timeline

21:55 – Beachhead Market & Early Adopters

23:25 – B2B Model With Consumer Influence

25:40 – Handling Direct Patient Interest

27:38 – Who Is Not a Fit for Vessl

28:49 – What Sydney Would Do With $100M

30:06 – Direct-to-Consumer Possibilities

34:32 – Industry Consolidation & Exits

36:30 – Key Industry Players

37:58 – Why the Product Resonates With Patients

38:41 – Upcoming Conferences & Events

39:25 – Closing & Call to Action

Are you a medtech CEO in need of some marketing help attracting investors, growing sales pipeline, and more? Go to ⁠⁠GrowMyMedtech.com⁠⁠ to book time for a free analysis.

Subscribe to our Youtube Channel

⁠⁠https://www.youtube.com/channel/UCGpL_rGt1LQJwinMq_K7gfg⁠⁠

Subscribe to our LinkedIn Newsletter

⁠⁠https://www.stateofmedtechpodcast.com/⁠⁠

Follow The State of MedTech on

LinkedIn ⁠⁠https://www.linkedin.com/company/thestateofmedtech⁠⁠

Instagram ⁠⁠https://www.instagram.com/stateofmedtech/⁠⁠

TikTok ⁠⁠https://www.tiktok.com/@stateofmedtech⁠⁠

X ⁠⁠https://twitter.com/StateofMedTech⁠⁠

Facebook ⁠⁠https://www.facebook.com/stateofmedtech/⁠⁠

Follow Omar M. Khateeb on

LinkedIn ⁠⁠https://www.linkedin.com/in/okhateeb/⁠⁠

Instagram ⁠⁠https://www.instagram.com/omar.m.khateeb/⁠⁠

TikTok ⁠⁠https://www.tiktok.com/@omarkhateebofficial⁠⁠

X ⁠⁠https://twitter.com/OmarMKhateeb⁠⁠

Facebook ⁠⁠https://www.facebook.com/OmarMKhateeb/

#MedtechLeadership #Prosthetics #HealthcareBusiness #CEOInsights #PatientCare

From rural Tennessee to the top of Stryker, John Brown grew a $17M company into a $4.3B market leader, not with hype, but with discipline, culture, and calculated bets. Omar shares Brown’s most valuable leadership lessons and why they still matter today.

Episode Breakdown:

00:00 – The unlikely path of John Brown

00:54 – How this episode came to life

01:23 – Meeting Cy Johnson and researching Brown’s story

02:51 – Why Brown stands apart from other medtech CEOs

03:34 – His impact by the numbers 09:07 – Lesson 1: Decentralize or die

10:56 – Lesson 2: The 20% growth law 12:26 – Building a culture of performance

15:47 – Lesson 3: Invent it, make it, sell it 16:47 – Lesson 4: Culture is king 17:12 – Lesson 5: Hire smart, humble hustlers

18:26 – Lesson 6: Make bold bets at the right time

18:48 – The Howmedica acquisition and integration pause

20:07 – Final years and succession planning

20:52 – Lesson 7: Legacy equals culture plus succession

21:20 – Why Brown’s leadership still matters today

23:20 – Advice for the next generation

23:45 – Closing thoughts and sponsor mentions

Are you a medtech CEO in need of some marketing help attracting investors, growing sales pipeline, and more? Go to ⁠GrowMyMedtech.com⁠ to book time for a free analysis.

Subscribe to our Youtube Channel

⁠https://www.youtube.com/channel/UCGpL_rGt1LQJwinMq_K7gfg⁠

Subscribe to our LinkedIn Newsletter

⁠https://www.stateofmedtechpodcast.com/⁠

Follow The State of MedTech on

LinkedIn ⁠https://www.linkedin.com/company/thestateofmedtech⁠

Instagram ⁠https://www.instagram.com/stateofmedtech/⁠

TikTok ⁠https://www.tiktok.com/@stateofmedtech⁠

X ⁠https://twitter.com/StateofMedTech⁠

Facebook ⁠https://www.facebook.com/stateofmedtech/⁠

Follow Omar M. Khateeb on

LinkedIn ⁠https://www.linkedin.com/in/okhateeb/⁠

Instagram ⁠https://www.instagram.com/omar.m.khateeb/⁠

TikTok ⁠https://www.tiktok.com/@omarkhateebofficial⁠

X ⁠https://twitter.com/OmarMKhateeb⁠

Facebook ⁠https://www.facebook.com/OmarMKhateeb/

Stroke affects over 800,000 people in the U.S. each year and remains one of the top causes of death and disability worldwide. In this episode, Rapid Medical CEO Ronen Eckhouse joins to discuss their FDA-cleared TigerTrever device, the DriveWire navigation breakthrough, and the first-ever robotic thrombectomy procedure. Learn how Rapid Medical is transforming clot retrieval safety, speed, and outcomes.

Are you a medtech CEO in need of some marketing help attracting investors, growing sales pipeline, and more? Go to GrowMyMedtech.com to book time for a free analysis.

Subscribe to our newsletter: https://www.stateofmedtechpodcast.com/

Subscribe to our Youtube Channel

https://www.youtube.com/channel/UCGpL_rGt1LQJwinMq_K7gfg

Follow The State of MedTech on:

• LinkedIn
• Instagram
• Tiktok
• X
• Facebook

Follow Omar M. Khateeb on

• ⁠LinkedIn⁠
• ⁠Instagram⁠
• ⁠Tiktok⁠
• ⁠X⁠
• ⁠Facebook⁠

Episode breakdown:

00:00 – Tech Problems, AV Chaos, and Starting the Conversation

00:50 – Meet Adrian Mendes, CEO of Perimeter Medical

01:27 – How Perimeter Got on the Radar (and Chamath’s Backing)

02:17 – Chamath Explains the Breast Cancer Surgery Problem

04:47 – AI + Imaging to Eliminate Repeat Surgeries

06:34 – FDA Trials, Labeling, and the Road to Approval

07:23 – The Emotional and Clinical Impact of Re-Excisions

08:35 – How Surgeons Use Perimeter’s Current FDA-Cleared Device

09:52 – $700M Wasted Annually on Repeat Surgeries

10:59 – Cutting Re-Excisions to 5%: Hospital and Patient Benefits

12:07 – Why Medtech Needs Both Clinical and Economic Pathways

12:58 – Adrian’s AI Hardware Background and Move to Medtech

14:55 – How Optical Coherence Tomography (OCT) Works in the OR

16:27 – Imaging Comparison: OCT vs. Ultrasound vs. MRI vs. Pathology

17:59 – Building an AI + OCT Platform and Tissue Registry

19:22 – The Scale of the Market Opportunity Beyond Breast Cancer

20:55 – Why Breast Cancer Was the Beachhead Market

21:53 – Perimeter’s Business Model: Capital, Disposables, and AI Software

23:33 – Adoption, Workflow Integration, and Surgeon Response

25:49 – Confidence, Data, and Surgeon Feedback

27:02 – Demand Creation and Word-of-Mouth Growth

28:59 – Workflow Demo: How the Device Is Used in Surgery

30:49 – Patient Impact: Rural Access and Reduced Delays

32:31 – AI Levels the Playing Field for Community Hospitals

33:53 – PMA Submission and AI Clinical Trial Results (88.1% Accuracy)

35:57 – The Emotional Benefit of “First-Time-Right” Cancer Surgery

37:20 – Regulatory Progress and Commercial Updates

38:44 – Chamath’s Involvement and Why AI Differentiates Perimeter

40:05 – Quality Data vs. Big Data: Building a Proprietary Library

41:13 – Predictive Health, Earlier Detection, and Future Applications

42:24 – TechMed vs. Medtech: Why Perimeter Is a True Hybrid

43:07 – Looking Ahead: More Indications and Expanding Applications

43:53 – Closing Thoughts and Call to Action

Are you a medtech CEO in need of some marketing help attracting investors, growing sales pipeline, and more? Go to GrowMyMedtech.com to book time for a free analysis.

Subscribe to our Youtube Channel

https://www.youtube.com/channel/UCGpL_rGt1LQJwinMq_K7gfg

Subscribe to our LinkedIn Newsletter

https://www.stateofmedtechpodcast.com/

Follow The State of MedTech on

LinkedIn https://www.linkedin.com/company/thestateofmedtech

Instagram https://www.instagram.com/stateofmedtech/

TikTok https://www.tiktok.com/@stateofmedtech

X https://twitter.com/StateofMedTech

Facebook https://www.facebook.com/stateofmedtech/

Follow Omar M. Khateeb on

LinkedIn https://www.linkedin.com/in/okhateeb/

Instagram https://www.instagram.com/omar.m.khateeb/

TikTok https://www.tiktok.com/@omarkhateebofficial

X https://twitter.com/OmarMKhateeb

Facebook https://www.facebook.com/OmarMKhateeb/

Episode breakdown

00:00 – Why You Shouldn’t Wait to Start Your Capital Raise

00:34 – The Hidden Cost of Fundraising & Building Public Visibility

00:53 – Intro: The State of Medtech with Omar Khateeb

01:08 – Meet Colleen Gray: From Entrepreneur to Investment Banker

01:38 – Why Raising Capital Is Harder in 2024

02:13 – Colleen’s Journey: Tech to Orthopedics CEO to US Capital SVP

04:18 – Lessons from Building and Selling Companies

05:16 – Joining US Capital and What They Do for Medtech Founders

06:18 – Today’s Challenging Fundraising Landscape Explained

07:20 – How Founders Can Stand Out and Capture Investor Attention

08:46 – Avoiding Common Fundraising Mistakes

10:53 – Who Should Approach US Capital and When?

13:06 – How to Use Early Funds Correctly (and Mistakes to Avoid)

14:45 – Why Understanding Reimbursement Early Matters

16:33 – Build for a Market, Not Just a Technology

18:55 – The Role of Market Intelligence Tools (Compass, AlphaSophia)

19:35 – Thinking Beyond Equity: Creative Financing Options

20:28 – Forecasting with Milestones Investors Care About

21:26 – Proving You Can Deliver on Promises Builds Confidence

23:34 – First-Time Founders: How to Earn Investor Trust

24:49 – Why Storytelling and Conviction Matter in Your Pitch

26:03 – Inspiring Confidence Without a Track Record

27:49 – Why Product Alone Doesn’t Win Investment

28:10 – Building a Sales Model Investors Will Trust

29:06 – Be Conservative in Your Revenue Forecasts

30:00 – Valuations: How to Justify Your Number in This Market

31:39 – Choosing the Right Investors Beyond Just the Check

33:00 – Lessons Learned: Taking Money You Regret

34:58 – How to Push Back on Investors (and Why You Should)

36:29 – Building an Investor-Ready Financial Model

38:19 – How Much to Spend on IP Protection at Each Stage

40:08 – When to Hire a Reputable IP Law Firm

41:10 – Grants and State Venture Programs as Capital Sources

42:26 – The Importance of Expert Guidance and Networking

43:54 – Matching Your Pitch to Angels vs. Institutional Investors

46:04 – One Key Fundraising Tip and One Pitfall to Avoid

47:43 – Closing Thoughts and Founder Call-to-Action

48:01 – Support the Show and Subscribe

Learn more about LSI’s market intel platform and amazing investor summits at LS-Intel.com

Are you a medtech CEO in need of some marketing help attracting investors, growing sales pipeline, and more? Go to GrowMyMedtech.com to book time for a free analysis.

Subscribe to our Youtube Channel

https://www.youtube.com/channel/UCGpL_rGt1LQJwinMq_K7gfg

Subscribe to our LinkedIn Newsletter

https://www.stateofmedtechpodcast.com/

Follow The State of MedTech on

LinkedIn https://www.linkedin.com/company/thestateofmedtech

Instagram https://www.instagram.com/stateofmedtech/

TikTok https://www.tiktok.com/@stateofmedtech

X https://twitter.com/StateofMedTech

Facebook https://www.facebook.com/stateofmedtech/

Follow Omar M. Khateeb on

LinkedIn https://www.linkedin.com/in/okhateeb/

Instagram https://www.instagram.com/omar.m.khateeb/

TikTok https://www.tiktok.com/@omarkhateebofficial

X https://twitter.com/OmarMKhateeb

Facebook https://www.facebook.com/OmarMKhateeb/

Episode Breakdown:

00:00 – Intro

00:21 – Why materials matter in medical device design

01:14 – Dr. Upma Sharma’s path from engineer to medtech CEO

03:01 – Arsenal’s founding story with Bob Langer and George Whitesides

06:20 – DARPA’s battlefield challenge and the birth of Rescue Foam

10:15 – How “Fix-a-Flat” foam saves lives internally

11:44 – Neocast: A liquid embolic inspired by toothpaste physics

14:33 – How Arsenal removes the “art” from embolic injections

16:14 – Arsenal’s pipeline across trauma, neuro, and women’s health

19:26 – Why chronic brain bleeds may surpass stroke

22:38 – How Arsenal approaches spinouts and strategic exits

23:42 – Fundraising goals and IDE milestones

25:49 – Clinicians’ role in shaping product development

28:14 – The broader potential of Arsenal’s biomaterials platform

29:48 – First-in-human data coming to SNIS and LSI London

30:12 – Outro

Are you a medtech CEO in need of some marketing help attracting investors, growing sales pipeline, and more? Go to GrowMyMedtech.com to book time for a free analysis.

Subscribe to our newsletter: https://www.stateofmedtechpodcast.com/

Subscribe to our Youtube Channel

https://www.youtube.com/channel/UCGpL_rGt1LQJwinMq_K7gfg

Follow The State of MedTech on:

• ⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠
• ⁠⁠⁠⁠Instagram⁠⁠⁠⁠
• TikTok
• ⁠⁠⁠⁠X
• ⁠⁠⁠⁠Facebook⁠⁠⁠⁠

Follow Omar M. Khateeb on

• ⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠
• ⁠⁠⁠⁠Instagram⁠⁠⁠⁠
• TikTok
• ⁠⁠⁠⁠X
• ⁠⁠⁠⁠Facebook⁠⁠